<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02475213</url>
  </required_header>
  <id_info>
    <org_study_id>CP-MGA271-03</org_study_id>
    <nct_id>NCT02475213</nct_id>
  </id_info>
  <brief_title>Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer</brief_title>
  <official_title>A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab and in Combination With MGA012 in Patients With Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer, Urothelial Cancer, and Other Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MacroGenics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MacroGenics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of enoblituzumab (MGA271) in combination&#xD;
      with Keytruda (pembrolizumab) when given to patients with B7-H3-expressing melanoma, squamous&#xD;
      cell carcinoma of the head and neck (SCCHN), non small cell lung cancer (NSCLC), Urothelial&#xD;
      Cancer and other B7-H3 expressing cancers. The study will also evaluate what is the highest&#xD;
      dose of enoblituzumab that can be given safely when given with pembrolizumab. Assessments&#xD;
      will also be done to see how the drug acts in the body (pharmacokinetics (PK),&#xD;
      pharmacodynamics) and to evaluate potential anti-tumor activity of MGA271 in combination with&#xD;
      pembrolizumab. Safety and efficacy of enoblituzumab in combination with MGA012 (anti-PD-1&#xD;
      monoclonal antibody; also known as INCMGA00012) will also be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">August 18, 2021</completion_date>
  <primary_completion_date type="Actual">August 18, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>one year</time_frame>
    <description>Adverse Events, Serious Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration</measure>
    <time_frame>7 weeks</time_frame>
    <description>PK of MGA271 in combination with pembrolizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that develop anti-drug antibodies</measure>
    <time_frame>One year</time_frame>
    <description>Proportion of patients who develop anti-MGA271 antibodies, immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tumor volume RECIST 1.1 criteria</measure>
    <time_frame>Weeks 6, 15, 24, 33, 42, 51</time_frame>
    <description>Anti-tumor activity of MGA271 in combination with pembrolizumab and in combination with MGA012 using both conventional RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tumor volume using immune-related RECIST criteria</measure>
    <time_frame>Weeks 6, 15, 24, 33, 42, 51</time_frame>
    <description>Anti-tumor activity of MGA271 in combination with pembrolizumab and in combination with MGA012 using immune-related RECIST criteria.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">145</enrollment>
  <condition>Melanoma</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Urethelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1: enoblituzumab 3 mg/kg plus pembrolizumab 2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>enoblituzumab 3 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: enoblituzumab 10 mg/kg plus pembrolizumab 2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>enoblituzumab 10 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: enoblituzumab 15 mg/kg plus pembrolizumab 2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>enoblituzumab 15 mg/kg IV weekly plus pembrolizumab 2 mg/kg IV every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: enoblituzumab 15 mg/kg plus MGA012 375 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>enoblituzumab 15 mg/kg IV weekly plus MGA012 375 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Enoblituzumab</intervention_name>
    <description>enoblituzumab is administered by IV infusion once per week for up to 51 doses.</description>
    <arm_group_label>Cohort 1: enoblituzumab 3 mg/kg plus pembrolizumab 2 mg/kg</arm_group_label>
    <arm_group_label>Cohort 2: enoblituzumab 10 mg/kg plus pembrolizumab 2 mg/kg</arm_group_label>
    <arm_group_label>Cohort 3: enoblituzumab 15 mg/kg plus pembrolizumab 2 mg/kg</arm_group_label>
    <arm_group_label>Cohort 4: enoblituzumab 15 mg/kg plus MGA012 375 mg</arm_group_label>
    <other_name>MGA271</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab is administered by IV infusion every 3 weeks for up to 17 doses.</description>
    <arm_group_label>Cohort 1: enoblituzumab 3 mg/kg plus pembrolizumab 2 mg/kg</arm_group_label>
    <arm_group_label>Cohort 2: enoblituzumab 10 mg/kg plus pembrolizumab 2 mg/kg</arm_group_label>
    <arm_group_label>Cohort 3: enoblituzumab 15 mg/kg plus pembrolizumab 2 mg/kg</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MGA012</intervention_name>
    <description>anti-PD-1 monoclonal antibody</description>
    <arm_group_label>Cohort 4: enoblituzumab 15 mg/kg plus MGA012 375 mg</arm_group_label>
    <other_name>INCMGA00012</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically-proven, unresectable, locally advanced or metastatic melanoma, SCCHN,&#xD;
             NSCLC, and other cancers that express B7-H3.&#xD;
&#xD;
          -  Melanoma that has progressed during or following at least 1 and up to 5 prior systemic&#xD;
             treatments for unresectable locally advanced or metastatic disease, or melanoma&#xD;
             patients who are intolerable of or have refused standard cancer therapy. Pre- and&#xD;
             on-study biopsy required.&#xD;
&#xD;
          -  SCCHN that has progressed during or following at least 1 and up to 5 prior systemic&#xD;
             treatments for metastatic or recurrent disease deemed to be incurable. Patient who&#xD;
             refuse radical resection for recurrent disease or are intolerant of or refused&#xD;
             standard first line therapy are eligible to enroll&#xD;
&#xD;
          -  NSCLC that has progressed during or following 1 - 5 prior systemic therapies for&#xD;
             unresectable locally advanced or metastatic disease (at least one docetaxel,&#xD;
             gemcitabine, or platinum analogue based therapy), or are intolerant of or refused&#xD;
             standard cancer therapy. For squamous cell carcinoma, or adenocarcinoma without known&#xD;
             activating mutation: the prior systemic therapy is at least one platinum analogue. For&#xD;
             adenocarcinoma with known activating driver mutation: the prior systemic therapy is at&#xD;
             least TKI directed&#xD;
&#xD;
          -  Urothelial cancer arising in the bladder, renal pelvis, ureter or urethra that has&#xD;
             progressed during or following at least 1 and up to 5 prior systemic treatments for&#xD;
             unresectable locally advanced or metastatic disease (includes anti-PD-L1,anti-PD-1,&#xD;
             but excludes other experimental therapies). Patients must have received at least one&#xD;
             platinum-containing regimen (e.g., gemcitabine/cisplatin [GC], dose-dense&#xD;
             methotrexate/vinblastine/doxorubicin/cisplatin [DDMVAC], or&#xD;
             carboplatinum/gemcitabine). No more than 5 prior systemic regimens allowed.&#xD;
&#xD;
          -  Measurable disease per RECIST 1.1 criteria&#xD;
&#xD;
          -  Easter Cooperative Oncology Group (ECOG) performance status 0 or 1&#xD;
&#xD;
          -  Acceptable laboratory parameters and adequate organ reserve.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of symptomatic central nervous system metastases, unless&#xD;
             treated and asymptomatic&#xD;
&#xD;
          -  Patients with history of autoimmune disease with certain exceptions such as vitiligo,&#xD;
             resolved childhood atopic dermatitis, psoriasis not requiring systemic therapy within&#xD;
             the past 2 years, patients with history of Grave's disease that are now euthyroid&#xD;
             clinically and by lab testing&#xD;
&#xD;
          -  History of allogeneic bone marrow, stem cell, or solid organ transplant&#xD;
&#xD;
          -  Treatment with systemic cancer therapy or investigational therapy within 4 weeks of&#xD;
             first study drug administration; radiation within 2 weeks; corticosteroids (greater&#xD;
             than or equal to 10 mg prednisone or equivalent per day) or other immune suppressive&#xD;
             drugs within 2 weeks of first study drug administration&#xD;
&#xD;
          -  Trauma or major surgery within 4 weeks of first study drug administration&#xD;
&#xD;
          -  History of clinically-significant cardiovascular disease; gastrointestinal&#xD;
             perforation; gastrointestinal bleeding, acute pancreatitis or diverticulitis within 4&#xD;
             weeks of first study drug administration&#xD;
&#xD;
          -  Active viral, bacterial, or systemic fungal infection requiring parenteral treatment&#xD;
             within 7 days of first study drug administration&#xD;
&#xD;
          -  Known history of hepatitis B or C infection or known positive test for hepatitis B&#xD;
             surface antigen or core antigen, or hepatitis C polymerase chain reaction (PCR)&#xD;
&#xD;
          -  Known positive testing for human immunodeficiency virus or history of acquired immune&#xD;
             deficiency syndrome&#xD;
&#xD;
          -  Known hypersensitivity to recombinant proteins, polysorbate 80, or any excipient&#xD;
             contained in the drug or vehicle formulation for MGA271 or pembrolizumab.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chet Bohac, PharmD MD MSc</last_name>
    <role>Study Director</role>
    <affiliation>MacroGenics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic - AZ</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health Services, Inc.</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - FL</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute Research Program</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Greenbaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics, LLC - Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - MN</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Institute</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania/Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburg</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 16, 2015</study_first_submitted>
  <study_first_submitted_qc>June 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2015</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

